NewAmsterdam Pharma N.V.

NASDAQ: NAMS · Real-Time Price · USD
25.38
0.21 (0.83%)
At close: Aug 15, 2025, 1:20 PM

NewAmsterdam Pharma Statistics

Share Statistics

NewAmsterdam Pharma has 112.63M shares outstanding. The number of shares has increased by 24.72% in one year.

112.63M
24.72%
2.23%
85.79%
62.4M
38
n/a

Short Selling Information

The latest short interest is 6.88M, so 6.13% of the outstanding shares have been sold short.

6.88M
6.13%
7.31%
8.15

Valuation Ratios

The PE ratio is -10.04 and the forward PE ratio is -14.01. NewAmsterdam Pharma's PEG ratio is -0.53.

-10.04
-14.01
53.22
100.3
3.2
-15.23
-0.53
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for NewAmsterdam Pharma.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 8.08, with a Debt / Equity ratio of 0.

8.08
8.08
0
n/a
n/a
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
$670.04K
$-3.55M
68
0.05
n/a

Taxes

-1K
0%

Stock Price Statistics

The stock price has increased by 43.19% in the last 52 weeks. The beta is -0.01, so NewAmsterdam Pharma's price volatility has been lower than the market average.

-0.01
43.19%
20.68
20.91
67.65
846,190

Income Statement

In the last 12 months, NewAmsterdam Pharma had revenue of 45.56M and earned -241.6M in profits. Earnings per share was -2.56.

45.56M
45.56M
-176.29M
-241.6M
-241.49M
-241.6M
-2.56
Full Income Statement

Balance Sheet

The company has 771.74M in cash and 448K in debt, giving a net cash position of 771.29M.

771.74M
448K
771.29M
n/a
815.11M
733.34M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -158.56M and capital expenditures -672K, giving a free cash flow of -159.24M.

-158.56M
-672K
-159.24M
-1.69
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -386.91% and -530.25%.

100%
-386.91%
-530.25%
-530.25%
-530%
-386.91%
-349.49%

Dividends & Yields

NAMS does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for NAMS is $41, which is 68% higher than the current price. The consensus rating is "Buy".

$41
68%
Buy
10
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

45.84
3